| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -159,506 | -102,630 |
| Stock-based compensation expense | 16,463 | 11,944 |
| Change in fair value of derivative liability | -65 | -76 |
| Depreciation and amortization | 3,478 | 2,217 |
| Amortization of right-of-use assets | 2,167 | 1,425 |
| Net accretion of discount on marketable securities | 3,587 | 2,433 |
| Prepaid expenses and other current assets | -2,741 | 7 |
| Other assets | 5,119 | 5,129 |
| Accounts payable | 2,477 | 4,314 |
| Accrued and other liabilities | 5,780 | 798 |
| Deferred revenue | -119 | -29 |
| Operating lease liabilities | -2,343 | -1,529 |
| Net cash used in operating activities | -137,633 | -91,135 |
| Purchase of marketable securities | 264,721 | 249,480 |
| Maturities of marketable securities | 301,201 | 268,273 |
| Acquisition of property and equipment | 606 | 697 |
| Net cash provided by (used in) investing activities | 35,874 | 18,096 |
| Issuance of common stock upon exercise of stock options and warrants | 118 | 2 |
| Issuance of common stock - 2020 espp | 860 | 860 |
| Net cash provided by financing activities | 978 | 862 |
| Net decrease in cash and cash equivalents | -100,781 | -72,177 |
| Cash and cash equivalents at beginning of period | 149,336 | - |
| Cash and cash equivalents at end of period | 48,555 | - |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)